Rolls Royce sold more cars than ever | AstraZeneca snapped up a biotech firm |
Finimize

Hi John, here's what you need to know for January 10th in 3:04 minutes.

🫦 Once bitten, twice shy – especially after a pretty tooth-and-nail 2022. Join Endowus’s Samuel Rhee for Preparing Your Strategy For A Volatile 2023 and Beyond tomorrow, and find out how to stop volatility sinking its teeth into your portfolio this year. Get your free ticket

Today's big stories

  1. Rolls-Royce sold a record number of its uber-luxe cars last year
  2. Here are five resolutions you’ll want to consider if you’re investing in crypto – Read Now
  3. AstraZeneca announced it’s buying US drugmaker CinCor

High-Rolling Royce

High-Rolling Royce

What’s Going On Here?

Rolls-Royce Motor Cars announced on Monday that it cruised to a record number of sales last year.

What Does This Mean?

2022 was a tough year, but there was consolation in the fact that we all faced some struggles. Some of us panicked about rent, others stressed about mortgage rates, and the uber-rich faced stark decisions like whether to choose a “Dark Emerald” Rolls-Royce or one in a charming shade called “Iguazu Blue”. See, despite the war putting a halt to Russian orders and Covid sapping demand in China, the UK-based carmaker could rely on gung-ho US demand to help it sell just over 6,000 vehicles last year – the highest annual figure in its 119-year history. And these weren't just any old Rolls-Royces: no, these beauties were decked out with all the trimmings, from boot-mounted racing drone holders to custom paint jobs – pushing the average price past $500,000 for the first time. That might be why the firm’s expecting to deliver a record profit when it reports results in the coming weeks.

Why Should I Care?

The bigger picture: Eminent emirates.
The Middle East was leading the charge on those fancy Rolls-Royce customizations – and that could tell us something about the future of luxury. After all, Barclays analysts predict the region will become one of the fastest growing luxury markets in 2023, and with high oil prices propping up its economies and tourism growing, that’s not too hard to believe.

Zooming out: Unlucky for some.
Rolls-Royce's record sales are the exception, not the rule. Data out earlier this month showed that US new vehicle sales hit their lowest point since 2011 last year (tweet this). And things could get even worse: inventory levels have been climbing, so if demand doesn’t grow, we could end up in a "demand destruction" scenario where supply outstrips demand. And that's a bad deal for carmakers: either they slash their prices (and profit), or they wind up with a fleet of unsold cars.

Copy to share story: https://go.finimize.com/wp/news/high-rolling-royce/

🙋 Ask a question

Analyst Take

Five Things Thou Shalt Do About Crypto In 2023

Five Things Thou Shalt Do About Crypto In 2023

By Jonathan Hobbs, Analyst

Last year was bad for crypto investors like, biblically bad: bitcoin and ether crashed about 65%, and those were among the top performers of the lot. 

But if you’re a devout and patient crypto investor, and you’ve got faith in the blockchain’s long-term prospects, 2023 could be a good year to build up your crypto stack at lower prices. 

So that’s today’s Insight: five things to do this year to prepare for the next crypto bull run.

Read or listen to the Insight here

Finimize x Revolut

They say you can’t put a price on knowledge, so we didn’t.

Now you can get six free months of Finimize Premium, meaning you can sink your teeth into our expert analysts’ Insights without paying a penny.

And when you’re ready to put that knowledge to use, you can enjoy three months of free Revolut Premium too.

We’ll even send you £10 or equivalent as a thank you for reading this far.

Our community wants to know your name

Building a good brand is hard work.

So if you’re proud of the work you do, you best make sure everyone knows about it.

You could start by introducing yourself to our one-million-strong community: they’re a global bunch of switched-on, savvy retail investors who want to take their investing skills up a notch.

And if your tips, tools, or platform – plus whatever else you have up your sleeve – could help them do that, then this might be just the right spot for you to show off what you have to offer.

Make sure everyone knows your name: introduce yourself to over one million retail investors.

Get In Touch

Blood Brothers

Blood Brothers

What’s Going On Here?

AstraZeneca agreed to buy US drugmaker CinCor on Monday, infusing some life into the ailing firm.

What Does This Mean?

CinCor has been having a hard time. Back in November, work on its flagship blood pressure drug baxdrostat hit a rough patch, with a disappointing trial triggering an investor tizzy that knocked shares down over 50%. That kerfuffle got AstraZeneca’s attention, though, and the pharma giant swept in with an offer to buy the US biotech company for $26 a share on Monday – a cool 121% more than the stock was worth just last Friday, bringing the value of the deal to $1.3 billion. And get this: CinCor shareholders will get an extra $10 per share if and when the baxdrostat drug is submitted for regulatory approval. That's a win-win: AstraZeneca can fast-track the drug through clinical trials, and potentially combine it with its own fast-growing kidney disease treatment – and CinCor shareholders get a sweet, sweet payday.

Why Should I Care?

For markets: Eat or be eaten.
Get used to seeing deals like this in the world of pharma. A report out from EY on Monday estimated that global pharmaceutical companies will lose a whopping $200 billion a year in sales between now and 2030, as top-selling drugs lose their patents. Their likely solution: snap up small fry to add promising new drugs to their pipelines. And they’ve got the cash to do it, with analysts estimating they're sitting on a record $1.4 trillion right now.

The bigger picture: Watch this space.
These giants won't just be going after anyone, mind you. The grim economic outlook has hit everyone’s appetite for risk, so they'll be on the lookout for small firms whose drugs show promise or are already making sales. For savvy investors who want to cash in on the trend then, that's where you could strike gold.

Copy to share story: https://go.finimize.com/wp/news/blood-brothers/

🙋 Ask a question

💬 Quote of the day

“I’ve been on a diet for two weeks and all I’ve lost is two weeks.”

– Totie Fields (an American comedian)
Tweet this

🌍 Finimize Live

🥳 Coming Up This Week…

All events in UK time.

🌪 Preparing Your Strategy For A Volatile 2023 And Beyond: 12pm, January 11th
🤑 Wealth Building Habits With Carl Richards And Helena Wardle: 5pm, January 11th
🙋‍♀️ Ladies Investing Club: 6.30pm, January 11th
🎙 Live Q&A With Finimize CEO Max Rofagha: 1pm, January 12th
👩‍💻 2023 Investing Opportunities For The Self-Employed: 10am, January 13th

👀 And After That…

🌍 Investing 101: Where To Invest In 2023: 1pm, January 16th
💥 How To Spot The Best Long-Term Investments: 1pm, January 17th
📈 How To Hedge Against Volatility With Crypto: 5pm, January 19th
📑 The Risks And Regulations When Investing In Crypto: 10am, January 27th

🎯 On Our Radar

  1. Read it and weep. This tool can tell educators if ChatGPT wrote a student’s essay.
  2. Succubus chic. Check out the sultry, scary look taking the fashion world by storm.
  3. Little but long-lived. Hummingbirds might hold the secrets we need to help slow aging.
  4. Cactus leather. Check out the wonder-material that’s inspiring everyone from COS to Karl Lagerfeld.
  5. Set it and forget it. Automating your savings goals can be a game-changer.
❤️ Share with a friendYour Referrals: 0

Thanks for reading John. If you liked today's brief, we'd love for you to share it with a friend.

Share your unique link:

https://finimize.com/invite/?kid=12T6MV

You stay classy, John 😉

We’d love to hear your thoughts. Give feedback

Want to advertise with us too? Get in touch

Image Credits:

Image credits: Angelina Dimitrova, Maksim Denisenko - Shutterstock | Asli Pehlivanli

Preferences:

Update your email or change preferences

View in browser

Unsubscribe from all Finimize Emails

😴

Crafted by Finimize Ltd. | Bow Bells House, Bread Street, London, EC4M 9HH

All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2021

View Online